Gene: SEC16B

89866
LZTR2|PGPR-p117|RGPR|RGPR-p117|SEC16S
SEC16 homolog B, endoplasmic reticulum export factor
protein-coding
1q25.2
Ensembl:ENSG00000120341 MIM:612855 Vega:OTTHUMG00000167206 UniprotKB:Q96JE7
NC_000001.11
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.162e-1 (AD)  1.471e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FOCAD0.895
EML60.894
PHTF10.892
PPIP5K10.891
HERC10.886
ZNF385B0.883
POLR3A0.883
PTPRT0.882
VWA70.878
PTPN30.876

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MDFI-0.523
YES1-0.516
LRAT-0.511
RAB13-0.498
HEY2-0.496
BCL7C-0.479
COPZ2-0.463
REST-0.46
S100A16-0.459
ROM1-0.455

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0067181,12-benzoperylene"1,12-benzoperylene results in increased expression of SEC16B mRNA"26377693
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SEC16B mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of SEC16B mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SEC16B mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SEC16B mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SEC16B mRNA"25510870
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of SEC16B mRNA"21346803
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SEC16B mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC16B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC16B mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of SEC16B mRNA21420995|2906747
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of SEC16B mRNA24449571
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SEC16B mRNA20106945
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SEC16B mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of SEC16B mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SEC16B mRNA28628672
D019327Copper SulfateCopper Sulfate results in decreased expression of SEC16B mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of SEC16B mRNA20106945
D016572CyclosporineCyclosporine results in decreased expression of SEC16B mRNA19770486
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SEC16B mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SEC16B mRNA28628672
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of SEC16B mRNA27392435
D005485FlutamideFlutamide results in decreased expression of SEC16B mRNA24793618
D005485FlutamideFlutamide results in increased expression of SEC16B mRNA24136188
D017313FenretinideFenretinide results in decreased expression of SEC16B mRNA28973697
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SEC16B mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SEC16B mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SEC16B mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SEC16B mRNA28628672
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of SEC16B mRNA27392435
C544151jinfukangjinfukang results in increased expression of SEC16B mRNA27392435
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SEC16B mRNA28001369
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of SEC16B protein24625837
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of SEC16B mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of SEC16B mRNA"25554681
D009532NickelNickel results in decreased expression of SEC16B mRNA24768652|2558310
C016030pantogabpantogab results in decreased expression of SEC16B mRNA17379144
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SEC16B mRNA"25510870
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of SEC16B mRNA19710929
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SEC16B mRNA19710929
D010936Plant ExtractsPlant Extracts results in decreased expression of SEC16B mRNA23557933
D011441PropylthiouracilPropylthiouracil results in decreased expression of SEC16B mRNA24780913
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of SEC16B mRNA25895662
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SEC16B mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SEC16B mRNA19770486
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SEC16B mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SEC16B mRNA21724226
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SEC16B mRNA26232522
D013853ThioacetamideThioacetamide results in increased methylation of SEC16B promoter27914986
C012589trichostatin Atrichostatin A results in increased expression of SEC16B mRNA24935251
D014520UrethaneUrethane results in decreased expression of SEC16B mRNA28818685
D014635Valproic AcidValproic Acid results in decreased expression of SEC16B mRNA29154799
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC16B mRNA"27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0007029endoplasmic reticulum organization-IBA21873635  
GO:0007029endoplasmic reticulum organization-IDA21768384  
GO:0007030Golgi organization-IBA21873635  
GO:0007031peroxisome organization-IDA21768384  
GO:0010628positive regulation of gene expression-IMP21768384  
GO:0015031protein transport-IEA-  
GO:0016559peroxisome fission-IMP21768384  
GO:0048208COPII vesicle coating-IBA21873635  
GO:0048208COPII vesicle coating-TAS-  
GO:0070863positive regulation of protein exit from endoplasmic reticulum-IBA21873635  
GO:0070863positive regulation of protein exit from endoplasmic reticulum-IMP21768384  
GO:0070973protein localization to endoplasmic reticulum exit site-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0005829cytosol-TAS-  
GO:0012507ER to Golgi transport vesicle membrane-IBA21873635  
GO:0043231intracellular membrane-bounded organelle-IDA21768384  
GO:0070971endoplasmic reticulum exit site-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-199977ER to Golgi Anterograde TransportTAS
R-HSA-199991Membrane TraffickingTAS
R-HSA-204005COPII-mediated vesicle transportTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-446203Asparagine N-linked glycosylationTAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-948021Transport to the Golgi and subsequent modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
20712903Obesity and diabetes genes are associated with being born small for gestational age: results from the Auckland Birthweight Collaborative study. (2010 Aug 16)Morgan ARBMC Med Genet